Primary biliary cholangitis (PBC) Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Primary Biliary Cholangitis is a chronic, presumable autoimmune liver diseases which further leads to progressive cholestasis and often end-stage liver diseases. This disease was formerly called as Primary Biliary Cirrhosis. PBC is the most common disease of women. Symptoms of PBC includes fatigue, pruritus, right upper quadrant discomfort, hepatomegaly, hyperpigmentation, jaundice, splenomegaly, xerophthalmia, kayser-fleischer rings etc.
Generally 25% of patients with PBC can be diagnosed by routine blood evaluation. Diagnosis of PBC includes evaluation of levels of ceruloplasmin, bile acids, serum hyaluronate, determination of presence of antimitochondrial antibodies (AMAs) in serum by ELISA and Complement Fixation Test. Imaging studies of PBC is done by Ultrasonography, CT Scan or MRI.
Ursodeoxycholic acid (UDCA) is the main treatment for people with PBC and Obeticholic acid (OCA) is a new treatment that works by improving bile flow and reducing inflammation. Medications like antibiotics can be given to treat other symptoms of PBC like pruritis. If the liver is completely damaged then Liver transplantation is recommended.
By Trial Phase, Primary Biliary Cholangitis pipeline drugs are segmented as:
By Company, Primary Biliary Cholangitis pipeline drugs are segmented as:
By Molecule, Primary Biliary Cholangitis pipeline drugs are segmented as:
By Route of Administration, Primary Biliary Cholangitis pipeline drugs are segmented as:
Primary Biliary Cholangitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Primary Biliary Cholangitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Primary Biliary Cholangitis disease pipeline drugs development. This report studies the dynamics of the Primary Biliary Cholangitis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Primary Biliary Cholangitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.